WHO Signs MoU with IGBA for Promoting the Access to Biosimilars and Generics

 WHO Signs MoU with IGBA for Promoting the Access to Biosimilars and Generics

WHO Signs MoU with IGBA for Promoting the Access to Biosimilars and Generics

Shots:

  • The memorandum of understanding signed between WHO and International Generic and Biosimilar Medicines Association to facilitates the approval of generics and biosimilars thus reduces the burden of clinical trials for biosimilars and increases the access to drugs
  • The WHO’s efforts to increase the access to Biosimilar includes List of International Comparators, providing information on reference products that can be used in clinical studies and its prequalification program, assessing the quality, safety, and efficacy of medicinal products
  • The independent study by McKinsey estimated that WHO prequalification saves the world up to $590M/year. Additionally, WHO provides Biowaiver List which describes generic medicines that are eligible for a waiver from studies

Click here to­ read full press release/ article | Ref: WHO | Image: United Nations

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post